Personalized fibrinogen dose for heart surgery patients
Treatments studied
Part of Blood & lymphatic, Heart & circulation clinical trials.
This trial tests a personalized dose of fibrinogen, a protein that helps blood clot, for people having heart surgery with a heart-lung machine. The goal is to see if a tailored dose works better than a fixed dose after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are having heart surgery that uses a heart-lung machine
- Your doctor decides you need fibrinogen after the surgery
- You have health insurance through the French social security system
- You agree to take part in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what happens when a drug called fibrinogen (which helps blood clot) is paid for by insurance during complex heart surgeries. It aims to see if having this drug covered changes how much blood is needed or how long you stay in the hospital.
This trial checks if a fast bedside test for fibrinogen (a protein that helps blood clot) can help guide treatment for trauma patients who are actively bleeding. It may lead to better care in the emergency department.
This trial tests whether giving a clotting protein called fibrinogen helps control bleeding during a liver transplant from a deceased donor. It may be a good option if you have certain liver conditions or lower fibrinogen levels.
This trial tests a new device that quickly measures fibrinogen (a protein that helps blood clot) from a small blood sample during surgery for type A aortic dissection. It aims to help doctors make faster decisions about blood clotting treatments.
This trial tests a medicine called 4F-PCC to stop bleeding during complex heart surgery that uses a heart-lung machine. It could help people who have bleeding problems after the surgery.
This trial tests a medicine called fibrinogen concentrate (CSL511) to see if it helps control bleeding during a special surgery (cytoreductive surgery with HIPEC) for pseudomyxoma peritonei (PMP). The goal is to reduce the need for blood transfusions and improve safety.
Hear when a new Fibrinogen Deficiency in Complex Cardiac Surgery trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.